Initial Remibrutinib (oral, covalent, and highly specific inhibitor of Bruton’s tyrosine kinase (BTK)) data in SS shows good efficacy and safety. Plenary Abs 1113 #ACR22 @RheumNow https://t.co/5Zr0Y1ueAv https://t.co/Iy194YUWNC

• Remibrutinib (LOU064) in Sjögren’s Syndrome: Safety and Efficacy Results from a…

RheumNow’s expanded coverage of the #ACR22 annual meeting is sponsored in part by Novartis. All content chosen by RheumNow & its Faculty.

DANBIO registry: 1600+ pts RA, AxSpA, PsA Infiximab biosimilar to biosimilar switch (CT-P13 -> GP1111) Maintenance at 1yr: >80% > withdrawal in original IFX naive, but higher BL DA Do second time switchers do better because of past switch experience? Abs#1112 #ACR22 @RheumNow https://t.co/IgjhGLVESz

2nd Plenary Session! Remibrutinib (BTK inhibitor) for treatment of Sjögren's syndrome (phase 2 study) Improvement of ESSDAI, salivary flow and pathologically elevated Ig's Abs#1113 @RheumNow #ACR22 https://t.co/vdgxBPe6qd

We're used to originator-to-biosimilar switches. Widespread biosim use means we now see biosim-biosim switches (incl as second switch) DANBIO data retention good I see the hallmarks of nocebo still an issue I think we can all agree: ongoing education important #ACR22 @RheumNow https://t.co/6PcMfEEozk

Yes. But this only accounts for 1/3 of risk to develop clinical RA. We need a better understanding of the other 2/3 so we can propose efficient preventive interventions. #ACR22 @RheumNow https://t.co/RRzlAISFK3

• https://twitter.com/doctorRBC/status/1591825586401710080

@EBRheum @RheumNow Its more than that…tubulointerstitial kidney disease, lymph nodes, salivary gland, and hepatobiliary tract disease don’t show findings of vasculitis. Certain HLA haplotypes more linked with autoimmune diseases are present. #ACR @RheumNow

@AlexisOgdie et al: PsA pts who were MDA, DAPSA LDA, or ACR50 responders vs non-responders reported clinically meaningful improvements across PROs including pain, physical function, fatigue, and work productivity. Abs 1019 #ACR22 @RheumNow https://t.co/MK13sXS3Or https://t.co/TfCrQMV2JX

• Association Between Stringent Clinical Measures of Disease Activity and Clinica…

Presence of DFS pattern should not be used to indiscriminately exclude presence of a rheumatic disease based on retrospective study in Abs 0814. RA, SS and Raynaud's ICD10 codes were higher among DFS pattern ANA per chart review. #ACR22 @RheumNow https://t.co/mLtppvR4dk https://t.co/6Lukxntqe7

• Clinical Correlation of Dense Fine Speckled (DFS) Pattern of ANA - ACR Meeting …

Biosimilar to biosimilar effective in treatment of RA/PsA/AxSpA. Large study looking at infliximab biosimilar switching - resulted in high retention rates and virtually no change in disease activity. @RheumNow #ACR22 Abs#1112 https://t.co/uNRXLewo4M

The greater the PsAID score, the more likely escalation in PsA treatment. Noted significant correlation between PsAID and physician global scores. Do you use PsAID in your clinic? Abs 1028 #ACR22 @RheumNow https://t.co/gcjm2XgPE3 https://t.co/bKPtXz5Nw8

• How Does PsAID Implementation Affect Treatment Intensification and Patient Sati…

Abstr #1494 determinants of clinically important worsening (CIW) of early axSpA - CIW = ASDAS ↑ > 0.9 b/w 2 visits - Tender Joint count and ASAS-NSAID score associated w/ CIW - MRI SI Jt inflammation & structural damage predictive of CIW @RheumNow #ACR22 https://t.co/Dgeh25BaWM

Global survey of rheumatic irAE people (me included) Standard case Variable answers, broadly distributed none are wrong We'll move from expert extrapolation of concepts to data-driven answers, with the right foundations👍 ABST0776 @MDAndersonNews @msalmazor #ACR22 @RheumNow https://t.co/5gMzWuCXd7

Do patients with PsA like online wellness programs? #ACR22 @RheumNow 🌈 186 patients, 86% women, 90% White 🌈sleep and nutrition were highly rated for wellness 🌈cost and fatigue barriers to adopting wellness behaviors 🌈 27% were open to an online wellness program

BASDAI and ASDAS performed similarly in axPsA pts, both demonstrating weak correlations w/ peripheral arthritis and moderate/strong correlations w/ pt fatigue and pain. Abs 1037 #ACR22 @RheumNow https://t.co/WRQx1hkIll https://t.co/kJVIWyVv2w

• Performance of BASDAI vs. ASDAS in Evaluating Axial Involvement in Patients wit…